Observational studyBMJ open diabetes research & care2025
Hemoglobin A1c time-in-range, mortality, and diabetes complications in older adults with diabetes.
Observational study in BMJ open diabetes research & care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionHemoglobin A1c (A1c) treatment goals in older adults often consider life expectancy and comorbidities. A1c stability may also inform the risks of major outcomes. We studied the association of individualized A1c time-in-range (A1c TIR) with mortality and diabetes complications. RESEARCH DESIGN AND
methodsWe conducted a retrospective observational cohort study of patients with diabetes, 65 years or older, from the Department of Veterans Affairs (VA) and Kaiser Permanente (KP) from 2004 to 2018. Patients had at least four A1c tests during a 3-year baseline, and A1c TIR was calculated as the percentage of days when A1c levels were within patient-specific target ranges. We estimated associations among A1c TIR and mortality, cardiovascular, and microvascular outcomes using time to event models and instrumental variable (IV) models.
resultsWe identified 386 287 VA patients and 24 885 KP patients with a mean age of 74.3 years (SD 5.8) and 72.3 years (SD 5.7), respectively. Among VA patients, when compared with higher A1c TIR (80-100%), lower A1c TIR (0% to <20%) was associated with increased mortality (HR, 1.22; 95% CI 1.20 to 1.23) and cardiovascular outcomes (HR, 1.10; 95% CI 1.07 to 1.13). IV models showed similar associations. Among KP patients, lower A1c TIR (0% to <20%) was associated with mortality (HR, 1.36; 95% CI 1.27 to 1.45). IV models showed associations with increased mortality and cardiovascular outcomes. Among both VA and KP patients, greater A1c time below and time above range were associated with increased mortality.
conclusionsA1c stability within patient-specific target ranges is associated with a lower risk of major adverse outcomes among older adults with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.